Boehringer Ingelheim

Spotlight – Nash in 2023 and beyond
EP Vantage
Thu, 08/3/23 - 10:03 am
NASH
Boehringer Ingelheim
Zealand Pharma
Akero Therapeutics
Axcella Health
Eli Lilly
Pfizer
Ionis Pharmaceuticals
Cascade
AstraZeneca
Gilead Sciences
Novo Nordisk
Ascletis Pharma
MediciNova
Boehringer Ingelheim posts more Jardiance growth as potential US kidney disease approval nears
Fierce Pharma
Tue, 08/1/23 - 10:35 pm
Boehringer Ingelheim
Jardiance
diabetes
earnings
Biosimilar makers split strategies in bid to take on top-selling Humira
BioPharma Dive
Thu, 07/27/23 - 10:25 am
biosimilars
Humira
AbbVie
rebates
drug pricing
Amgen
Celltrion
Novartis
Boehringer Ingelheim
Biocon
Fresenius
Sandoz
Organon
Coherus
AbbVie's Skyrizi delivers head-to-head win versus Amgen's Otezla in psoriasis
Fierce Pharma
Wed, 07/26/23 - 11:37 am
AbbVie
Skyrizi
Amgen
Otezla
Boehringer Ingelheim
psoriasis
Jardiance cleared in EU for CKD, challenging Forxiga
Pharmaphorum
Wed, 07/26/23 - 09:45 am
Boehringer Ingelheim
Eli Lilly
Jardiance
Europe
chronic kidney disease
Forxiga
Novo Nordisk, Eli Lilly and Boehringer Ingelheim back bill to bring obesity drug coverage to Medicare
Fierce Pharma
Thu, 07/20/23 - 09:42 pm
Novo Nordisk
Eli Lilly
Boehringer Ingelheim
obesity
7 companies are rolling out Humira biosimilars
Drugstore News
Wed, 07/12/23 - 09:44 am
AbbVie
Humira
biosimilars
Boehringer Ingelheim
Organon
Samsung Bioepsis
Sandoz
Fresenius Kabi
Celltrion
Coherus Biosciences
Biocon
Boehringer's new data drop shows 19% weight loss for phase 2 obesity prospect
Fierce Biotech
Sun, 06/25/23 - 09:46 pm
Boehringer Ingelheim
obesity
clinical trials
Zealand Pharma
survodutide
Sanofi says arbitration court rejects Boehringer's Zantac claims
Reuters
Wed, 06/21/23 - 10:53 am
Sanofi
Boehringer Ingelheim
Zantac
legal
FDA Approves New Class of Medicines to Treat Pediatric Type 2 Diabetes
Benzinga
Tue, 06/20/23 - 09:46 pm
Eli Lilly
Boehringer Ingelheim
Jardiance
Synjardy
type 2 diabetes
pediatric
FDA
Late-stage pipeline for idiopathic pulmonary fibrosis is small but growing
Clinical Trials Arena
Mon, 06/19/23 - 11:39 am
IPF
Roche
Esbriet
Pirespa
Boehringer Ingelheim
Ofev
Yuhan makes $325M cancer bet to challenge Boehringer, Takeda
Fierce Pharma
Wed, 05/31/23 - 06:59 pm
Yuhan
cancer
Boehringer Ingelheim
Takeda
HER2 inhbitor
non-small cell lung cancer
Zealand, Boehringer's drug meets main weight-loss goal in mid-stage trial
BioSpace
Wed, 05/10/23 - 10:21 am
Boehringer Ingelheim
Zealand Pharma
obesity
clinical trials
BI 456906
Boehringer Ingelheim to Mine Ginkgo’s Molecules in $406M Undruggable Targets Deal
BioSpace
Mon, 05/8/23 - 11:30 pm
Boehringer Ingelheim
Ginko Bioworks
bioactive molecules
Boehringer Ingelheim to surf with Melbourne-based biotech in $181M neuropsychiatric therapy deal
Fierce Biotech
Fri, 05/5/23 - 11:53 am
Boehringer Ingelheim
Kinoxis Therapeutics
neuropsychiatric
Boehringer Ingelheim breaks ground on €285M API plant in Germany
Fierce Pharma
Wed, 05/3/23 - 11:35 am
Boehringer Ingelheim
drug manufacturing
Germany
Boehringer Ingelheim opens new biotechnology R&D center in Germany
Pharmaceutical Business Review
Tue, 04/25/23 - 10:42 am
Boehringer Ingelheim
Germany
R&D
Playing catch-up, Boehringer taps RetinAI for AI boost to eye disease R&D
Fierce Biotech
Fri, 04/21/23 - 10:14 am
Boehringer Ingelheim
RetinAI
artificial intelligence
geographic atrophy
R&D
Most-clicked pharma news for week ending April 1 2023: Signify Health acquisition, Ferring Research Institute shutdown, Jardiance sales increase, and more
CP Wire
Mon, 04/3/23 - 03:35 pm
CVS Health
Signify Health
M&A
Ferring Pharmaceuticals
Pfizer
Bristol Myers Squibb
Eli Lilly
Novo Nordisk
Boehringer Ingelheim
Jardiance
Ozempic
drug pricing
Eliquis
CMS
Most-clicked pharma news for week ending April 1 2023: Signify Health acquisition, Ferring Research Institute shutdown, Jardiance sales increase, and more
Mon, 04/3/23 - 03:33 pm
CVS Health
Signify Health
M&A
Ferring Pharmaceuticals
Pfizer
Bristol Myers Squibb
Eli Lilly
Novo Nordisk
Boehringer Ingelheim
Jardiance
Ozempic
drug pricing
Eliquis
CMS

Pages